Italy In-Vitro Diagnostics Market Size

Italy In-vitro Diagnostics Market Analysis

The Italy in-vitro diagnostics market is expected to grow at a CAGR of 7.5% over the forecast period.

The studied market was significantly affected by the COVID-19 pandemic, with adverse effects during the initial phase due to lockdowns and shutdowns. For instance, according to a report by the Higher Institute of Health in 2022, it was reported that the screening tests for breast, colorectal, and cervical cancer decreased by 37.6%, 45.5%, and 43.4% in Italy during the pandemic. However, with the sudden outbreak of COVID-19 in Italy, the demand for IVD products increased significantly during the pandemic in Italy. For instance, according to a report by European Centre for Disease Prevention and Control (ECDC), the total number of COVID-19 tests performed in Italy in 1st four weeks of 2021 was 5.5 million, which was increased to 7.5 million in the next four weeks of 2021. Thus, the pandemic increased the utilization of in-vitro diagnostic testing for COVID-19 detection, and it was instrumental in market growth during the pandemic. However, the decreased number of COVID-19 cases and the increased vaccination in Italy reduced the demand for in-vitro diagnostics for COVID-19 detection in the post-pandemic phase. 

The rising prevalence of chronic diseases is one of the primary factors driving market growth significantly. An increasing number of patients suffering from several chronic and infectious diseases is increasing the demand for early diagnosis using IVD devices. This is, in turn, increasing the adoption of in-vitro diagnosis for several conditions. For instance, according to an article published by Nova Agency in December 2022, the estimated number of new cancer cases was 390,700 in Italy in 2022. Similarly, according to the International Diabetes Federation (IDF), 4.47 million people in Italy had Diabetes in 2021, which was anticipated to increase to 4.59 million by 2045. Hence, the high disease prevalence among the Italian population is resulting in the increasing demand for early detection of diseases and driving the adoption of in-vitro diagnostic devices in the country.

Moreover, the major players in the country are actively focused on the innovation of technically advanced products, which is expected to benefit the country's target populationuntry for early disease detection. For instance, in May 2022, Mainz Biomed N.V., a molecular genetics diagnostic company, and Dante Labs, a genomics and precision medicine manufacturer, partnered to commercialize ColoAlert in Itoim to detect colorectal cancer at home. Thus, such developments are anticipated to fuel the adoption rate of these devices among the Italian population and drive market growth.

Therefore, the increasing prevalence of chronic diseases in the country and the availability of technically advanced products are expected to boost the in-vitro diagnostics market in Italy. However, the strict regulations applied to diagnostic products are expected to hinder market growth over the studied period.